STIM Key Statistics, Chart & Performance
The current stock price of STIM is 1.96 USD. In the past month the price increased by 39.23%. In the past year, price increased by 5.85%.
STIM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.29 | 219.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.95 | 207.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.35 | 145.84B | ||
| SYK | STRYKER CORP | 27.88 | 140.43B | ||
| BDX | BECTON DICKINSON AND CO | 14.23 | 58.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.49 | 56.88B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.91 | 49.08B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.21 | 40.16B | ||
| RMD | RESMED INC | 25.35 | 36.63B | ||
| DXCM | DEXCOM INC | 36.79 | 26.69B | ||
| PODD | INSULET CORP | 64.09 | 20.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.63 | 18.64B |
Related stock screener links
About STIM
Company Profile
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
Company Info
NEURONETICS INC
3222 Phoenixville Pike
Malvern PENNSYLVANIA 19355 US
CEO: Keith J. Sullivan
Employees: 716
Phone: 18776007555
NEURONETICS INC / STIM FAQ
What does NEURONETICS INC do?
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
What is the stock price of NEURONETICS INC today?
The current stock price of STIM is 1.96 USD. The price increased by 8.29% in the last trading session.
What is the dividend status of NEURONETICS INC?
STIM does not pay a dividend.
What is the ChartMill technical and fundamental rating of STIM stock?
STIM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is NEURONETICS INC worth?
NEURONETICS INC (STIM) has a market capitalization of 134.24M USD. This makes STIM a Micro Cap stock.
What is the outstanding short interest for NEURONETICS INC?
The outstanding short interest for NEURONETICS INC (STIM) is 18.11% of its float.
STIM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to STIM. When comparing the yearly performance of all stocks, STIM is a bad performer in the overall market: 82.63% of all stocks are doing better.
STIM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STIM. Both the profitability and financial health of STIM have multiple concerns.
STIM Financial Highlights
Over the last trailing twelve months STIM reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.59% | ||
| ROE | -162.68% | ||
| Debt/Equity | 2.4 |
STIM Forecast & Estimates
9 analysts have analysed STIM and the average price target is 6.63 USD. This implies a price increase of 238.27% is expected in the next year compared to the current price of 1.96.
For the next year, analysts expect an EPS growth of 55.83% and a revenue growth 105.05% for STIM